SD Biosensor Balance Sheet Health

Financial Health criteria checks 4/6

SD Biosensor has a total shareholder equity of ₩2,912.5B and total debt of ₩505.5B, which brings its debt-to-equity ratio to 17.4%. Its total assets and total liabilities are ₩3,767.7B and ₩855.2B respectively.

Key information

17.4%

Debt to equity ratio

₩505.45b

Debt

Interest coverage ratio	n/a
Cash	₩532.45b
Equity	₩2.91t
Total liabilities	₩855.22b
Total assets	₩3.77t

Recent financial health updates

Would SD Biosensor (KRX:137310) Be Better Off With Less Debt?

Aug 08

Recent updates

Financial Position Analysis

Short Term Liabilities: A137310's short term assets (₩928.2B) exceed its short term liabilities (₩159.3B).

Long Term Liabilities: A137310's short term assets (₩928.2B) exceed its long term liabilities (₩695.9B).

Debt to Equity History and Analysis

Debt Level: A137310 has more cash than its total debt.

Reducing Debt: Insufficient data to determine if A137310's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: A137310's debt is well covered by operating cash flow (32.5%).

Interest Coverage: Insufficient data to determine if A137310's interest payments on its debt are well covered by EBIT.

SD Biosensor Balance Sheet Health

Financial Health criteria checks 4/6

Key information

Recent financial health updates

Would SD Biosensor (KRX:137310) Be Better Off With Less Debt?

Recent updates

Third quarter 2024 earnings released: EPS: ₩532 (vs ₩552 loss in 3Q 2023)

What SD Biosensor, Inc's (KRX:137310) 25% Share Price Gain Is Not Telling You

Second quarter 2024 earnings released: ₩153 loss per share (vs ₩806 loss in 2Q 2023)

Would SD Biosensor (KRX:137310) Be Better Off With Less Debt?

Insufficient Growth At SD Biosensor, Inc (KRX:137310) Hampers Share Price

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: ₩91.00 loss per share (vs ₩2,177 loss in 1Q 2023)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Insufficient Growth At SD Biosensor, Inc (KRX:137310) Hampers Share Price

Upcoming dividend of ₩290 per share at 8.7% yield

Third quarter 2023 earnings released: ₩552 loss per share (vs ₩4,166 profit in 3Q 2022)

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 23%

New minor risk - Share price stability

SD Biosensor, Inc has completed a Follow-on Equity Offering in the amount of KRW 227.8 billion.

Upcoming dividend of ₩700 per share at 7.5% yield

Now 21% undervalued after recent price drop

SD Biosensor, Inc. Proposes Discontuation of Use and Disposal of Specific Pilot COVID-19 At-Home Tests in the United States Due to Microbial Contamination in the Liquid Disposal Solution

Full year 2022 earnings: EPS and revenues miss analyst expectations

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners completed the acquisition of Meridian Bioscience, Inc. (NasdaqGS:VIVO) from Impactive Capital LP, BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc, Royce & Associates, LP and others.

Investor sentiment deteriorated over the past week

Now 21% undervalued after recent price drop

Price target decreased to ₩56,500

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners (collectively, the "Consortium") entered into a definitive merger agreement to acquire Meridian Bioscience, Inc. (NasdaqGS:VIVO) for $1.5 billion.

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Consensus revenue estimates increase by 17%

SD BioSensor, Inc (KOSE:A137310) agreed to acquire Relab S.R.L. for KRW 61.9 billion.

SD BioSensor, Inc (KOSE:A137310) acquired bestbion dx - Diagnostische Produkte und Beratung GmbH for KRW 16 billion.

Investor sentiment deteriorated over the past week

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Discover healthy companies